Literature DB >> 15856156

[Neuroblastoma].

T Simon1.   

Abstract

Neuroblastoma is an embryonal tumour of childhood. Primary tumours are localized retroperitoneally or abdominally. Neuroblastoma produce catecholamine metabolites which are used as tumour markers. MIBG scintigraphy in addition to ultrasound and nuclear magnetic resonance tomography allow specific imaging of the tumour tissue. In young patients, spontaneous remissions are not uncommon, whereas the outcome in older children is poor despite intensive treatment. Therefore, the treatment of neuroblastoma must be risk adapted. The 5 year overall survival rates in the German NB97 trial were 96+/-1% in the observation group, 89+/-3% in the median risk group, and 50+/-3% in the high risk group.

Entities:  

Mesh:

Year:  2005        PMID: 15856156     DOI: 10.1007/s00120-005-0821-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

1.  New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.

Authors:  Thorsten Simon; Rüdiger Spitz; Andreas Faldum; Barbara Hero; Frank Berthold
Journal:  J Pediatr Hematol Oncol       Date:  2004-12       Impact factor: 1.289

2.  Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.

Authors:  Ruediger Spitz; Barbara Hero; Frank Westermann; Karen Ernestus; Manfred Schwab; Frank Berthold
Journal:  Genes Chromosomes Cancer       Date:  2002-07       Impact factor: 5.006

3.  The International Neuroblastoma Pathology Classification (the Shimada system).

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald; D O Stram; R B Gerbing; J N Lukens; K K Matthay; R P Castleberry
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

4.  Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

5.  Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.

Authors:  J M Maris; M J Weiss; C Guo; R B Gerbing; D O Stram; P S White; M D Hogarty; E P Sulman; P M Thompson; J N Lukens; K K Matthay; R C Seeger; G M Brodeur
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

6.  Neuroblastoma screening at one year of age.

Authors:  Freimut H Schilling; Claudia Spix; Frank Berthold; Rudolf Erttmann; Natalja Fehse; Barbara Hero; Gisela Klein; Johannes Sander; Kerstin Schwarz; Joern Treuner; Ulrich Zorn; Joerg Michaelis
Journal:  N Engl J Med       Date:  2002-04-04       Impact factor: 91.245

7.  Neuroblastoma preoperatively treated as nephroblastoma: does inadequate therapy worsen the prognosis?

Authors:  B Hero; N Graf; T Simon; A Weirich; J Tröger; F Berthold
Journal:  Klin Padiatr       Date:  2002 Jul-Aug       Impact factor: 1.349

8.  Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

Authors:  Thorsten Simon; Barbara Hero; Andreas Faldum; Rupert Handgretinger; Martin Schrappe; Dietrich Niethammer; Frank Berthold
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

Review 9.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

10.  The impact of surgical radicality on outcome in childhood neuroblastoma.

Authors:  D von Schweinitz; B Hero; F Berthold
Journal:  Eur J Pediatr Surg       Date:  2002-12       Impact factor: 2.191

View more
  1 in total

Review 1.  [Strabologic and neuro-ophthamologic aspects of childhood cancer].

Authors:  A Neugebauer; P Herkenrath; F Koerber; T Simon; A Brunn; M Deckert; J Fricke
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.